Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 24;11(2):144.
doi: 10.3390/antibiotics11020144.

Treatment of Severe Infections Due to Metallo-Betalactamases Enterobacterales in Critically Ill Patients

Jean-François Timsit  1   2 , Paul-Henri Wicky  1 , Etienne de Montmollin  1   2
Affiliations
Review

Treatment of Severe Infections Due to Metallo-Betalactamases Enterobacterales in Critically Ill Patients

Jean-François Timsit et al. Antibiotics (Basel). .

Abstract

Metallo-beta-lactamases-producing (MBL) Enterobacterales is a growing problem worldwide. The optimization of antibiotic therapy is challenging. The pivotal available therapeutic options are either the combination of ceftazidime/avibactam and aztreonam or cefiderocol. Colistin, fosfomycin, tetracyclines and aminoglycosides are also frequently effective in vitro, but are associated with less bactericidal activity or more toxicity. Prior to the availability of antibiotic susceptibility testing, severe infections should be treated with a combination therapy. A careful optimization of the pharmacokinetic/pharmacodynamic properties of antimicrobials is instrumental in severe infections. The rules of antibiotic therapy are also reported and discussed. To conclude, treatment of severe MBL infections in critically ill patients is difficult. It should be individualized with a close collaboration of intensivists with microbiologists, pharmacists and infection control practitioners.

Keywords: NDM; VIM; avibactam; aztreonam; bloodstream infections; cefiderocol; critically ill; metallo-beta-lactamases; pneumonia; sepsis.

PubMed Disclaimer

Conflict of interest statement

J.-F.T. reports advisory board participation for Pfizer, Shionoghi, Gilead, Beckton-Dickinson, Merck.

References

    1. Polemis M., Mandilara G., Pappa O., Argyropoulou A., Perivolioti E., Koudoumnakis N., Pournaras S., Vasilakopoulou A., Vourli S., Katsifa H., et al. COVID-19 and Antimicrobial Resistance: Data from the Greek Electronic System for the Surveillance of Antimicrobial Resistance-WHONET-Greece (January 2018–March 2021) Life. 2021;11:996. doi: 10.3390/life11100996. - DOI - PMC - PubMed
    1. Kazmierczak K.M., Karlowsky J.A., de Jonge B.L.M., Stone G.G., Sahm D.F. Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible Enterobacterales Collected as Part of a Global Surveillance Program, 2012 to 2017. Antimicrob. Agents Chemother. 2021;65:e0200020. doi: 10.1128/AAC.02000-20. - DOI - PMC - PubMed
    1. Sader H.S., Mendes R.E., Streit J.M., Carvalhaes C.G., Castanheira M. Antimicrobial susceptibility of Gram-negative bacteria from intensive care unit and non-intensive care unit patients from United States hospitals (2018–2020) Diagn. Microbiol. Infect. Dis. 2022;102:115557. doi: 10.1016/j.diagmicrobio.2021.115557. - DOI - PubMed
    1. Sader H.S., Castanheira M., Mendes R.E., Flamm R.K. Frequency and antimicrobial susceptibility of Gram-negative bacteria isolated from patients with pneumonia hospitalized in ICUs of US medical centres (2015–2017) J. Antimicrob. Chemother. 2018;73:3053–3059. doi: 10.1093/jac/dky279. - DOI - PubMed
    1. Babiker A., Clarke L.G., Saul M., Gealey J.A., Clancy C.J., Nguyen M.H., Shields R.K. Changing Epidemiology and Decreased Mortality Associated With Carbapenem-resistant Gram-negative Bacteria, 2000–2017. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2021;73:e4521–e4530. doi: 10.1093/cid/ciaa1464. - DOI - PMC - PubMed

LinkOut - more resources